Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Prime Medicine (PRME) Return on Equity (2022 - 2025)

Prime Medicine filings provide 4 years of Return on Equity readings, the most recent being 0.01% for Q4 2025.

  • On a quarterly basis, Return on Equity changed 0.0% to 0.01% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.01%, a 0.0% change, with the full-year FY2025 number at 0.01%, changed 0.0% from a year prior.
  • Return on Equity hit 0.01% in Q4 2025 for Prime Medicine, up from 0.02% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.01% in Q2 2022 to a low of 0.03% in Q4 2022.
  • Median Return on Equity over the past 4 years was 0.01% (2024), compared with a mean of 0.01%.
  • The widest YoY moves for Return on Equity: up 1bps in 2023, down -1bps in 2023.
  • Prime Medicine's Return on Equity stood at 0.03% in 2022, then surged by 54bps to 0.01% in 2023, then grew by 6bps to 0.01% in 2024, then decreased by -27bps to 0.01% in 2025.
  • The last three reported values for Return on Equity were 0.01% (Q4 2025), 0.02% (Q3 2025), and 0.02% (Q2 2025) per Business Quant data.